文献速递肝病

熊去氧胆酸治疗与原发性胆汁性胆管炎患者无肝移植生存

Ursodeoxycholic acid therapy and liver transplant-free survival in patients with primary biliary cholangitis.
PubMed 文献 · J Hepatol · 2019-04-11

这项国际队列研究基于全球PBC研究组数据库纳入8国3902例患者,比较熊去氧胆酸(UDCA)治疗与未治疗者的无肝移植生存。经逆概率治疗加权后,UDCA治疗者10年无肝移植生存率为79.7%,未治疗者为60.7%,UDCA与肝移植或死亡风险降低相关(HR 0.46)。

要点

  • UDCA治疗与PBC患者肝移植或死亡风险降低相关(HR 0.46,95%CI 0.40-0.52)。
  • 10年无肝移植生存率:UDCA治疗组79.7% vs 未治疗组60.7%(p<0.001)。
  • UDCA治疗1年后生化应答不佳者,其肝移植或死亡风险仍低于未治疗者(校正HR 0.56)。

核心结论

  • UDCA的使用可改善PBC患者的无肝移植生存,且不受疾病分期和所观察到的生化应答影响。
  • 这些发现支持UDCA作为PBC当前普遍的标准治疗。

研究设计与样本

  • 国际队列研究,纳入来自欧洲和北美8个国家的全球PBC研究组数据库患者,包括UDCA治疗和未治疗者。
  • 共纳入3902例患者,平均(SD)年龄54.3(11.9)岁,女性3552例(94.0%),UDCA治疗3529例(90.4%),未治疗373例(9.6%)。
  • 中位(四分位距)随访7.8(4.1-12.1)年,以肝移植和死亡为联合终点,采用逆概率治疗加权(IPTW)的Cox回归分析。

主要发现

  • UDCA治疗组721例、未治疗组145例死亡或接受肝移植。
  • IPTW后10年累积无肝移植生存率:UDCA治疗组79.7%(95%CI 78.1-81.2) vs 未治疗组60.7%(95%CI 58.2-63.4),p<0.001。
  • UDCA与肝移植或死亡风险降低相关(HR 0.46,95%CI 0.40-0.52;p<0.001),该风险比在所有疾病分期中均保持统计学显著。
  • UDCA治疗1年后被分类为生化应答不佳者,其肝移植或死亡风险低于未治疗者(校正HR 0.56;95%CI 0.45-0.69;p<0.001)。

临床怎么用

  • 作者认为这些发现支持UDCA作为PBC当前普遍的标准治疗。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: The clinical efficacy of ursodeoxycholic acid (UDCA) in primary biliary cholangitis (PBC) remains subject to debate as definitive randomized controlled trials are lacking. We aimed to determine whether UDCA prolongs liver transplant (LT)-free survival in patients with PBC. METHODS: This international cohort study included patients from the Global PBC Study Group database, originating from 8 countries in Europe and North America. Both UDCA-treated and untreated patients were included. LT and death were assessed as a combined endpoint through Cox regression analyses, with inverse probability treatment weighting (IPTW). RESULTS: In the 3,902 patients included, the mean (SD) age was 54.3 (11.9) years, 3,552 patients (94.0%) were female, 3,529 patients (90.4%) were treated with UDCA and 373 patients (9.6%) were not treated. The median (interquartile range) follow-up was 7.8 (4.1-12.1) years. In total, 721 UDCA-treated patients and 145 untreated patients died or underwent LT. After IPTW, the 10-year cumulative LT-free survival was 79.7% (95% CI 78.1-81.2) among UDCA-treated patients and 60.7% (95% CI 58.2-63.4) among untreated patients (p <0.001). UDCA was associated with a statistically significant reduced risk of LT or death (hazard ratio 0.46, 95% CI 0.40-0.52; p <0.001). The hazard ratio remained statistically significant in all stages of disease. Patients classified as inadequate biochemical responders after 1 year of UDCA had a lower risk of LT or death than patients who were not treated (adjusted hazard ratio 0.56; 95% CI 0.45-0.69; p <0.001). CONCLUSION: The use of UDCA improves LT-free survival among patients with PBC, regardless of the disease stage and the observed biochemical response. These findings support UDCA as the current universal standard of care in PBC. LAY SUMMARY: In this international multicenter study of 3,902 patients with primary biliary cholangitis, we found that treatment with ursodeoxycholic acid is associated with prolonged liver transplant-free survival. This association was significant, irrespective of sex, age, or disease stage. The survival benefit remained statistically significant in patients with an incomplete biochemical response to ursodeoxycholic acid therapy.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Harms MH, van Buuren HR, Corpechot C, et al. Ursodeoxycholic acid therapy and liver transplant-free survival in patients with primary biliary cholangitis. J Hepatol. 2019. PMID: 30980847. doi:10.1016/j.jhep.2019.04.001

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。